- Letter to the Editor
- Open Access
Histone de-acetylase inhibitors: a promising future for cancer treatment?
© Khan et al.; licensee BioMed Central Ltd. 2013
- Received: 13 September 2012
- Accepted: 5 March 2013
- Published: 11 March 2013
- Notch Signaling
- Antineoplastic Agent
- Bladder Carcinoma
- Notch Signaling Pathway
Histone de-acetylase proteins or lysine de-acetylases, represent a group of enzymes regulating DNA and gene expression by eliminating acetyl groups (de-acetylation) from lysine amino acids on histones and non-histone proteins[1, 2]. Histone de-acetylase functions normally by being involved in a series of cellular pathways like cell growth, cell cycle, signal transduction, notch signaling pathway and especially transcription. Although these functions allows histone de-acetylases to control expression of proteins involved in cancer initiation and cancer progression, abnormal acetylation of histone tails may occur with the resulting transcriptional lesions disrupting the apoptotic program of cells and leading to neoplasia[4, 5]. To counter, development of antineoplastic agents called histone de-acetylase inhibitors (HDIs) have been introduced to interact with the catalytic site and blocking substrate access of histone de-acetylases in proliferation of tumor cells. This anti-proliferative effect of HDIs in down regulation of BMI1 and c-MYC protein levels has shown promising results in treatment of the incurable AML as well as silencing estrogen receptor alpha in prevention of breast cancer[7, 8].
The precise molecular actions of HDIs are unclear with epigenetic pathways the proposed mechanism.
HDIs mainly induce activation of both intrinsic and extrinsic apoptotic pathways of neoplastic cells by affecting protein stability, protein-protein interactions through interference with the function of cell cycle proteins such as p21, inhibition of signaling pathways implicated with Raf/MEK and activation of Reactive Oxygen Species[10, 11]. In stress, HDIs acetylate DNA damage-response proteins, such as Ku70, causing the translocation of BAX to the mitochondria and activating apoptosis. Recently they have been known to cause autophagy of signaling pathways like mTOR, AIF which is a major development. Some studies have also shown HDIs contributing to growth suppression of primary tumors by enhancing tumor-cell’s immunogenicity via transcriptional activation of MHC (1/2) proteins and suppression of tumor angiogenesis by inhibition of hypoxia-induced VEGF expression[14, 15].
Despite the intrinsic anticancer potential, there are noteworthy limitations of these promising antineoplastic agents. Combinations of HDIs with other cancer modalities such as anthracyclines have been found to be effective in pre-clinical and clinical evaluation; however, their additive effect has also led to potential complexities such as resistance to anthracycline (doxorubicin) in leukaemia cells and augmentation of cardiac toxicity. Through modulation, HDIs also reactivate some latent viruses like human herpesvirus-6 predisposing to reinfection. However, resistance to HDACi-induced transformed cell death, as observed in clinical trials of human bladder carcinoma cells and prostate cancer cells and non-specific action against a large group of Histone de-acetylases forms the major limitations of these agents. Basis of this resistance is yet to be understood.
Regardless of the Food and Drug Administration (FDA) approval of Vorinostat (SAHA) and Romidepsin (ISTODAX) for the promising treatment of cutaneous T cell lymphoma, usage of HDIs as mono-therapies in other types of cancer has had moderate effects. Preclinical studies on cancers have concluded better synergistic and additive effects of HDIs with combination of chemotherapeutic drugs by helping improve HDIs therapeutic index. With complete and proper understanding of the major limitations of HDIs, their antitumor efficacy can be achieved enhancing the novel use of these anticancer drugs for the future treatments just like their current use as mood stabilizers and anti-epileptics.
- Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P: Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem. 2008, 283 (39): 26694-26704. 10.1074/jbc.M803514200.PubMedPubMed CentralView ArticleGoogle Scholar
- Choudhary C: Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009, 325 (5942): 834-840. 10.1126/science.1175371.PubMedView ArticleGoogle Scholar
- Bertos NR, Wang AH, Yang XJ: Class II histone deacetylases: structure, function, and regulation. Biochem Cell Biol. 2001, 79 (3): 243-252. 10.1139/o01-032.PubMedView ArticleGoogle Scholar
- Glozak MA, Seto E: Histone deacetylases and cancer. Oncogene. 2007, 26: 5420-5432. 10.1038/sj.onc.1210610.PubMedView ArticleGoogle Scholar
- Jacobson S, Pillus L: Modifying chromatin and concepts of cancer. Curr Opin Genet Dev. 1999, 9 (2): 175-184. 10.1016/S0959-437X(99)80027-6.PubMedView ArticleGoogle Scholar
- Johnstone R: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002, 1 (4): 287-299. 10.1038/nrd772.PubMedView ArticleGoogle Scholar
- Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, Oancea C, Brill B, Krämer OH, Serve H, Ruthardt M, Bug G: Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle. 2012, 11 (17): 3219-26. 10.4161/cc.21565.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhang Z, Yamashita H, Toyama T: Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res. 2005, 94 (1): 11-16. 10.1007/s10549-005-6001-1.View ArticleGoogle Scholar
- Monneret C: Histone deacetylase inhibitors for epigenetic therapy of cancer. Anticancer Drugs. 2007, 18 (4): 363-370. 10.1097/CAD.0b013e328012a5db.PubMedView ArticleGoogle Scholar
- Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC: Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol. 2005, 45: 495-528. 10.1146/annurev.pharmtox.45.120403.095825.PubMedView ArticleGoogle Scholar
- Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature. 2006, 6: 38-51.Google Scholar
- Rosato RR, Grant S: Histone Deactetylase inhibitors in cancer therapy. Cancer Biol Ther. 2009, 2 (1): 30-37.Google Scholar
- Robert T: HDACs link the DNA damage response, processing of double-strand breaks and autophagy. Nature. 471: 74-79.Google Scholar
- Magner WJ: Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000, 165 (12): 7017-7024.PubMedView ArticleGoogle Scholar
- Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007, 26: 5541-5552. 10.1038/sj.onc.1210620.PubMedView ArticleGoogle Scholar
- Ververis K, Karagiannis T:Overview of the classical histone deacetylase enzymes and histone deacetylase inhibitors. ISRN Cell Biology. 2012, 2012: 12-View ArticleGoogle Scholar
- Arbuckle JH, Medveczky PG: The molecular biology of human herpesvirus-6 latency and telomere integration. Microbes Infect. 2011, 13 (8–9): 731-741.PubMedPubMed CentralView ArticleGoogle Scholar
- Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, Chandra J: Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol. 2011, 2011: 514261-PubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.